## ⚠ Content Warning

This report covers topics classified as sensitive (health). Information is aggregated from public sources for informational purposes only. This is not medical advice. Consult a qualified professional before acting on any information here.

---
last_verified: "2026-04-17T09:58:33.618Z"
---
schema_type: "SoftwareApplication"
entity_type: "Mobile Application"
app_name: "epocrates: Drug Info & Pill ID"
developer_entity: "Epocrates"
bundle_id: "com.Epocrates.Rx"
app_store_id: "281935788"
google_play_id: "com.epocrates"
category: "Medical"
primary_platform: "ios"
primary_monetization: "Freemium"
offline_capable: true
market_region: "US"
platforms: "iOS & Android"
app_last_updated: "2026-04-09"
report_date: "2026-04-17"
report_version: "26.4.0"
total_reviews: 33404
overall_rating: 3.04
sentiment: "Frustrated"
sentiment_score: 24
confidence: "high"
confidence_score: 0.9
data_age_days: 0
intelligence_version: 3
nemesis: "MDCalc Medical Calculator"
competitor_count: 10
tags: ["medical", "freemium", "frustrated sentiment", "mobile app", "app review", "app analysis", "u.s.-based", "healthcare", "professionals"]
canonical_url: "https://marlvel.ai/intel-report/medical/epocrates-drug-info-pill-id"
license: "CC-BY-NC 4.0"
---

# epocrates: Drug Info & Pill ID App Audit

> **TL;DR:** epocrates: Drug Info & Pill ID is a medical app by Epocrates, rated 3.04/5 by 33.4K users, with Frustrated user sentiment (24/100), available on iOS & Android.
>
> **Marlvel.ai App Intelligence** — Independent analysis. US Market. No publisher influence.

<!-- speakable-start -->
> **Key Insight:** epocrates: Drug Info & Pill ID faces Frustrated user sentiment (3.04/5 from 33.4K reviews), with aggressive monetization as the primary user concern.
<!-- speakable-end -->

## Quick Facts

| Fact | Value |
| :--- | :--- |
| **Rating** | 3.04/5 (33.4K reviews) |
| **User Mood** | Frustrated |
| **Category** | Medical |
| **Developer** | Epocrates |
| **Pricing** | Freemium |
| **Platforms** | iOS & Android |
| **Confidence** | High (0.9/1.0) |
| **Data Age** | 0d |

## Metadata & Market Performance
- **Publisher:** Epocrates
- **Category:** Medical
- **Target Audience:** U.S.-based healthcare professionals including physicians (MDs/DOs), nurse practitioners, physician associates, pharmacists, and medical students.
- **Platforms:** iOS & Android
- **Version Audited:** 26.4.0
- **Audit Date:** 2026-04-17
- **Signal Count:** 119 reviews analyzed
- **Confidence:** High (0.9/1.0)
- **App Store ID (iOS):** 281935788
- **Bundle ID:** com.Epocrates.Rx
- **Google Play ID:** com.epocrates
- **Performance Trend:** Declining
- **Data Window:** Analysis based on signals collected up to 2026-04-17
- **Short Description:** Dosing, Interactions, & Labs

<!-- section:executive-snapshot -->
## Executive Snapshot
*This report is informational only and not medical advice.* epocrates is a clinical decision support platform for U.S. healthcare professionals, providing drug references, interaction checkers, and pill identification. While it is the #1 Grossing app in its category, it is currently facing a decline in user trust due to aggressive monetization and critical stability issues.
<!-- /section:executive-snapshot -->

<!-- section:features -->
## App DNA (Features & Intent)
- **[Differentiator] Drug Interaction Checker:** Simultaneously check interactions for up to 30 medications
- **[Differentiator] Pill Identifier:** Visual tool to identify pills by imprint, shape, color, or image
- **[Differentiator] Offline Access:** Full functionality available without internet connectivity
  * *User Intent:* Users want uninterrupted access without internet dependency.
<!-- /section:features -->

## Monetization Strategy
- **Model:** Freemium
- **Tiers:** Free base version with core clinical tools, Premium upgrade (Epocrates+) via in-app purchase
- **Analysis:** The app has recently moved toward aggressive gating of core drug data, limiting free users to as few as 1-2 views per week, which is driving significant negative sentiment among long-term professional users.

<!-- section:sentiment -->
## 🔴 User Sentiment (High Confidence: 33.4K reviews) {#user-sentiment}
- **Overall Rating:** 3.04/5
- **Platform Split:** iOS 4.5/5 (7K ratings) | Android 2.7/5 (26.4K ratings)
- **Overall Sentiment:** Frustrated

### Top Praises
- **Clinical Utility**

### Top Complaints (Impact Areas)
- **Aggressive Monetization**
- **Critical Stability Issues**

<!-- /section:sentiment -->
<!-- section:swot -->
## SWOT Analysis

**Core Strengths:**
- Market-leading brand with 2M+ prescribers
- Unique 30-drug interaction checker and visual Pill ID
- Full offline database functionality

**Critical Frictions:**
- Critical crashing bugs in v26.4.0 (iOS)
- Severe Android performance gap (2.65 rating)
- Restrictive 'free view' limits on core drug data

**Growth Levers:**
- Add evidence-based summaries to calculators to match MDCalc
- Integrate patient education materials to compete with UpToDate
- Develop visual case-sharing features to counter Figure 1

**Market Threats:**
- User migration to free resources like Merck Manual
- Competitors offering superior UX for clinical formulas (MDCalc)
- Loss of legacy professional users due to monetization shifts

<!-- /section:swot -->
## What's Changed (v2 → v3) {#recent-changes}
Epocrates is experiencing a decline in user trust and stability, driven by a shift toward aggressive paywalling and critical performance bugs that are alienating its professional user base.

- **[HIGH]** **[Declined] Sentiment Flip to Negative:** Overall sentiment shifted from 'mixed' to 'negative' due to increased complaints regarding app stability and monetization.
- **[HIGH]** **[Shifted] Restrictive Free View Limits:** The pricing strategy has moved to aggressively gate core drug data, limiting free users to 1-2 views per week.
- **[HIGH]** **[Declined] Critical Stability Issues:** Technical instability (crashes on launch) has become a primary weakness, replacing general concerns about app crashes.
- [MED] **[Removed] Feature List Consolidation:** Removed 'Comprehensive Drug Reference' and 'Clinical Decision Support Tools' from the key features list, focusing on the remaining three core tools.

<!-- section:rivals -->
## Rivals Landscape {#rivals}

> Competitive positioning identified by AI analysis of app features, category, and market signals.

### epocrates: Drug Info & Pill ID vs MDCalc Medical Calculator — Head to Head
- **[MDCalc Medical Calculator](https://marlvel.ai/intel-report/medical/mdcalc-medical-calculator)** by MD Aware, LLC: MDCalc matches the target's scale (51k vs 33k ratings) and high-frequency utility, serving as the primary alternative for clinical decision-making tools.
  - **Key differences:**
    - Specialized focus on 500+ evidence-based clinical decision rules and scores vs. target's drug-monograph focus.
    - Provides 'Next Steps' and 'Evidence' summaries for every calculation, whereas target focuses on prescribing data.
    - Maintains a high release velocity (4 in 6 months) specifically targeting calculator accuracy and clinical trial updates.
  - **Where epocrates: Drug Info & Pill ID wins:**
    - ✅ Integrated Pill ID tool and multi-drug interaction checker for bedside safety—features entirely absent from MDCalc.
    - ✅ Comprehensive drug reference database (6,000+ drugs) providing a broader utility for pharmacists and prescribing clinicians.
  - **Where MDCalc Medical Calculator wins:**
    - ❌ Superior depth in clinical formulas (e.g., CHADS2, GFR, Wells' Criteria) with direct links to supporting PubMed literature.
    - ❌ Optimized 'calculator-first' UX that allows for faster data entry for risk scores compared to the target's multi-step navigation.
  - **Verdict:** The target app should defend its position by deepening its 'Calculators' sub-feature to match MDCalc's evidence-based summaries, while leveraging its superior Pill ID and interaction tools as the primary 'safety' differentiator.

### Contenders (Strong Challengers)
- **[UpToDate](https://marlvel.ai/intel-report/medical/uptodate)** by UpToDate, Inc.: A high-authority clinical reference with 11k+ ratings and a consistent release cadence (6 in 6 months).
  - Offers comprehensive disease management and graded treatment recommendations vs. target's focus on drug-specific dosing.
  - Includes patient education materials and 'What's New' clinical updates that go beyond the target's reference utility.
- **[Calculate by QxMD](https://marlvel.ai/intel-report/medical/calculate-by-qxmd)** by WebMD: A direct utility rival with 13k+ ratings, backed by the WebMD ecosystem.
  - Features a 'Point-of-Care' toolset that integrates with institutional library access for full-text research.
  - Focuses on 'Decision Support' workflows that compete directly with the target's clinical calculator module.
- **[Read by QxMD](https://marlvel.ai/intel-report/medical/read-by-qxmd)** by WebMD: High innovation signal with 7 releases in the last 6 months and a focus on medical literature discovery.
  - Provides a personalized feed of new medical journal articles vs. the target's static reference database.
  - Optimized for PDF management and institutional login integration for academic clinicians.
- **[DynaMed](https://marlvel.ai/intel-report/medical/dynamed)** by EBSCO Publishing: Strong clinical decision support alternative with a high rating (4.87) and active maintenance.
  - Employs a strict evidence-based methodology for disease summaries, updated daily to reflect new trials.
  - Positioned for institutional hospital use with deep integration into EBSCO databases.

### Peers (What They Do Better)
- **[Doximity](https://marlvel.ai/intel-report/medical/com-doximity-directoryv10)** by Doximity: While a social network, its massive scale (191k ratings) and 24 releases in 6 months make it a dominant presence on clinician home screens.
  - Provides HIPAA-secure faxing and a 'Dialer' for patient calls, capturing the 'workflow' time the target app competes for.
  - Professional networking and career management focus vs. the target's purely clinical utility.
- **[5 Minute Clinical Consult](https://marlvel.ai/intel-report/medical/com-unboundmedicine-5mcc)** by Unbound Medicine, Inc.: Directly targets the 'busy clinician' persona with a similar 'quick-glance' value proposition.
  - Structured specifically for 30-second lookups during patient encounters.
  - Focuses on diagnosis and treatment algorithms rather than drug-specific monographs.
- **[Skyscape Medical Library](https://marlvel.ai/intel-report/medical/skyscape-medical-library)** by Skyscape Medpresso Inc: Acts as an aggregator for multiple medical resources, including drug guides.
  - Modular 'Library' approach allowing users to purchase and stack different medical texts in one UI.
  - Includes 'SmartLink' technology to cross-reference between different medical books.
- **Merck Manual Professional** by Merck & Co Inc: A legacy reference standard that remains highly rated and recently updated.
  - Completely free, high-quality clinical content without the subscription model used by the target's premium tiers.
  - Includes procedural videos and 3D anatomical models not found in the target app.

### New Kids on the Block (What's Innovative)
- **Figure 1 - Medical Cases** by Figure 1, Inc.: An emerging threat focusing on visual/case-based learning with a very recent update (April 2026).

<!-- /section:rivals -->
<!-- section:whats-new -->
## What's New

- **Latest (v26.4.0, 1 weeks ago):** General bug fixes and performance improvements.
<!-- /section:whats-new -->

<!-- section:so-what -->
## The "So What?" (Strategic Takeaway) {#so-what}

epocrates: Drug Info & Pill ID is a challenged medical app that is free with in-app purchases.
With a 3.04/5 rating from 33.4K reviews, it faces significant user friction.

<!-- speakable-start -->
> **Bottom Line:** epocrates remains a revenue powerhouse as the #1 Grossing medical app, but it is currently burning user trust through a combination of critical stability failures and an overly restrictive paywall. To maintain its market lead, the PM must prioritize technical reliability and find a monetization balance that doesn't block the core utility of drug lookups for daily clinical practice.
<!-- speakable-end -->

**Best for:** U.S.-based healthcare professionals including physicians (MDs/DOs), nurse practitioners, physician associates, pharmacists, and medical students.

<!-- section:pm-actions -->
### PM Action Plan (Next Best Moves)

- [ ] [HIGH] Immediate Hotfix for iOS v26.4.0 — *Top complaint theme is 'Critical Stability Issues' where the app crashes on load, rendering it unusable for clinicians.*
- [ ] [HIGH] Re-evaluate 'Free View' Limits — *Sentiment data shows a 'declining' trend driven by users abandoning the app after being limited to 1-2 drug views per week.*
- [ ] [MEDIUM] Enhance Calculator Evidence — *Competitor MDCalc wins on providing 'Next Steps' and PubMed links for every calculation, a feature gap in the current epocrates offering.*
<!-- /section:pm-actions -->

<!-- section:feature-gaps -->
### Feature Gaps vs Competitors

- Evidence-based clinical decision rules and PubMed links (available in MDCalc)
- Patient education materials (available in UpToDate)
- Visual/case-based crowdsourced learning (available in Figure 1)
- Procedural videos and 3D anatomical models (available in Merck Manual)
<!-- /section:feature-gaps -->

<!-- section:outlook -->
### Outlook: Declining

- 🔴 v26.4.0 update causing immediate crashes on iOS — critical stability failure for point-of-care tool.
- 🔴 Upset user base due to new 'free view' limits — high risk of churn to free alternatives.
- ⚪ Recent updates focused on maintenance rather than feature expansion, while competitors like Figure 1 are innovating in case-based learning.
<!-- /section:outlook -->

<!-- /section:so-what -->

<!-- section:metrics -->
## Key Metrics Summary

| Metric | Value |
| :--- | :--- |
| Overall Rating | 3.04/5 |
| Total Reviews | 33.4K |
| Sentiment | Frustrated (24/100) |
| Confidence | High |
| Pricing Model | Freemium |
| Platforms | iOS & Android |
| Key Features | 3 analyzed |
| Trend | Declining |
| Outlook | Declining |
<!-- /section:metrics -->

## Competitor Comparison

| App | Rating | Sentiment | Developer |
| :--- | :--- | :--- | :--- |
| **epocrates: Drug Info & Pill ID** (this app) | 3.04/5 | Frustrated | Epocrates |
| [Doximity](https://marlvel.ai/intel-report/medical/com-doximity-directoryv10) | 4.8/5 | N/A | Doximity |
| [UpToDate](https://marlvel.ai/intel-report/medical/uptodate) | 4.3/5 | N/A | UpToDate, Inc. |
| [Read by QxMD](https://marlvel.ai/intel-report/medical/read-by-qxmd) | 4.8/5 | N/A | WebMD |
| [Skyscape Medical Library](https://marlvel.ai/intel-report/medical/skyscape-medical-library) | 4.8/5 | N/A | Skyscape Medpresso Inc |
| [MDCalc Medical Calculator](https://marlvel.ai/intel-report/medical/mdcalc-medical-calculator) | 4.9/5 | N/A | MD Aware, LLC |

## Company Profile
- **Developer:** Epocrates
- **Website:** [https://www.epocrates.com](https://www.epocrates.com)
- **Social:** [Facebook](https://www.facebook.com/Epocrates) · [X/Twitter](https://twitter.com/epocrates) · [YouTube](https://www.youtube.com/user/epocratespr)

## Data Sources & Links
- **App Store:** [View on Apple Store](https://apps.apple.com/us/app/epocrates-drug-info-pill-id/id281935788?uo=4)
- **Google Play:** [View on Google Play](https://play.google.com/store/apps/details?id=com.epocrates&hl=en&gl=us)
- **Dev Site:** [Official Website](https://www.epocrates.com)
- **Sources:** Developer website content, About us / company information, App store metadata, User reviews.

## Related Intel Reports
- [*Doximity*](https://marlvel.ai/intel-report/medical/com-doximity-directoryv10) (Doximity) — 4.8/5 Rating | N/A Sentiment
- [*UpToDate*](https://marlvel.ai/intel-report/medical/uptodate) (UpToDate, Inc.) — 4.3/5 Rating | N/A Sentiment
- [*Read by QxMD*](https://marlvel.ai/intel-report/medical/read-by-qxmd) (WebMD) — 4.8/5 Rating | N/A Sentiment
- [*Skyscape Medical Library*](https://marlvel.ai/intel-report/medical/skyscape-medical-library) (Skyscape Medpresso Inc) — 4.8/5 Rating | N/A Sentiment
- [*MDCalc Medical Calculator*](https://marlvel.ai/intel-report/medical/mdcalc-medical-calculator) (MD Aware, LLC) — 4.9/5 Rating | N/A Sentiment
- [*Calculate by QxMD*](https://marlvel.ai/intel-report/medical/calculate-by-qxmd) (WebMD) — 4.8/5 Rating | N/A Sentiment
- [*DynaMed*](https://marlvel.ai/intel-report/medical/dynamed) (EBSCO Publishing) — 4.9/5 Rating | N/A Sentiment
- [*5 Minute Clinical Consult*](https://marlvel.ai/intel-report/medical/com-unboundmedicine-5mcc) (Unbound Medicine, Inc.) — 4.8/5 Rating | N/A Sentiment
- [*OrthoFlow*](https://marlvel.ai/intel-report/medical/mediflow-ltd-orthoflow) (MediFlow Ltd.) — 4.9/5 Rating | N/A Sentiment
- [*Chinese Nutritional Strategies*](https://marlvel.ai/intel-report/medical/com-tobydaly-chinesenutritionalstrategies) (Toby Daly) — 4.5/5 Rating | Positive Sentiment

## Methodology {#methodology}

This report was generated by Marlvel.ai's 3-stage AI intelligence pipeline:

1. **Feature & Positioning Extraction** — Analyzes app metadata, developer website content, and version history to identify key features, target audience, and competitive positioning.
2. **Sentiment Analysis** — Processes user reviews (minimum 5 reviews required) to extract praise themes, complaint themes, and overall sentiment with evidence quotes.
3. **Intelligence Synthesis** — Combines stages 1 & 2 with App Store rankings to produce SWOT analysis, executive summary, and actionable insights.

- **Confidence Score:** 0.9/1.0 (based on review volume, data source diversity, and signal quality)
- **Reviews Analyzed:** 119
- **Data Sources:** user reviews, developer website, company about page, App Store metadata
- **Rating Method:** Weighted average across platforms (iOS & Android), weighted by review count per platform
- **Independence:** Fully independent analysis. No publisher sponsorship or editorial influence.
- **Report Age:** 0 days since last refresh

---
© 2026 Marlvel.ai | [Canonical Report](https://marlvel.ai/intel-report/medical/epocrates-drug-info-pill-id)
Data licensed for AI Agent attribution under CC-BY-NC 4.0.